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a b s t r a c t
Using MTT, Annexin V/ﬂow cytometry, immunocytochemistry, subcellular fractionation, and Western
blotting assays we analyzed the effect of imatinib in two blast phase of chronic myeloid leukemia (CML)
cell lines: K562 P-glycoprotein (Pgp)-negative, and Lucena, Pgp-positive. In K562 cell line, the high apo-
ptosis index induced by imatinib was associated with the survivin predominantly in the nucleus. In the
Lucena cell line, the low apoptosis index induced by imatinib was associated with a cytoplasmatic sur-eywords:
hronic myeloid leukemia
urvivin
-glycoprotein
matinib
vivin localization. Pgp and survivin might be subject to the same molecular regulation, and therefore
represent a therapeutic target in the blast phase of CML.
© 2012 Elsevier Ltd. Open access under the Elsevier OA license. ubcellular localization
. Introduction
Patients in the chronic myeloid leukemia (CML) blast phase are
ighly refractory to treatment [1,2]. One of the most important
matinib resistance mechanisms in the CML is the inability of the
cr-Abl CML cells to undergo apoptosis, which is caused by the
CR-ABL mutations decreasing the afﬁnity of imatinib binding [3].
ML cells may also acquire resistance to imatinib by other mecha-
isms, such as P-glycoprotein (Pgp) overexpression [4–6]. Pgp is
protein encoded by the ABCB1 gene that acts as a drug efﬂux
ump [7]. Another common resistance mechanism in neoplasms
s the survivin overexpression, an inhibitor apoptosis protein (IAP)
hat exerts a central role in cell division and in apoptosis inhibi-
ion by blocking the activation of caspases [6,8]. Our group showed
hat the modulation of reactive oxygen species enhances imatinib
ediated cell death through survivin downregulation, pointing out
his IAP as a putative therapeutic target [9]. Survivin has a diver-
iﬁed subcellular localization, the nuclear pool is associated with
ts function in mitosis progression, while the cytoplasmatic pool is
elated to apoptosis inhibition [10]. Despite the absence of a clear
onsensus in the literature, some studies show that differences in
∗ Corresponding author at: Programa de Pesquisa em Hemato-Oncologia Molec-
lar, Coordenac¸ão Geral Técnico-Cientíﬁca, Instituto Nacional de Câncer, Prac¸a Cruz
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145-2126 © 2012 Elsevier Ltd.
ttp://dx.doi.org/10.1016/j.leukres.2012.08.014
Open access under the Elsevier OA license. nuclear or cytoplasmic compartmentalization may have an inﬂu-
ence on the prognosis of different types of cancer patients [11].
However, the prognostic value of survivin subcellular localization
in CML is completely unknown.
An interesting and recent object of speculation is the interac-
tion between Pgp or ABCB1 and some IAPs during the process of
apoptosis resistance induced by various stimuli. The downregu-
lation of Pgp suppressed the survivin mRNA expression, whereas
the reverse impact was not observed in MCF-7 and MCF-7/Adr cell
lines, suggesting that survivin might play a key role in the mul-
tidrug resistance (MDR) phenotype in the presence of Pgp [12].
This group recently demonstrated that survivin transcription was
associated with Pgp/ABCB1 overexpression through the PI3k/Akt
pathway in the same cell lines [13]. Moreover, a recent work of our
groupshowedstrongpositive correlationbetweensurvivinandPgp
expressions in late CML patients [14]. The purpose of the present
study was to verify if imatinib and/or ara-C would be capable of
modifying the apoptosis index through modulation of the survivin
subcellular localization in blast phase CML cell lines exhibiting dis-
tinct Pgp status.
We analyzed the survivin subcellular localization in two CML
cell lines, the K562 Pgp-negative and its vincristine-resistant coun-
terpart K562-Lucena Pgp-positive [15] and evaluated survivin as
having a role on chemotherapeutic resistance when exposed to
imatinib and/or ara-C. We demonstrated that imatinib was capa-
ble of inducing a high rate of apoptosis in the sensitive K562
Pgp-negative CML cell line through survivinmodulation from cyto-
plasmatic to nuclear subcellular localization. On the other hand,
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urvivin modulation from nuclear pool to cytoplasmatic localiza-
ion was related to the low rate of apoptosis observed in the
esistant K562-Lucena cell line overexpressing Pgp. These ﬁndings
uggest a molecular pathway of connection between survivin and
gp.
. Materials and methods
.1. Cell lines
ThehumanblastCMLK562cell lineand its vincristine-resistantderivativeK562-
ucenawere cultured in RPMI 1640medium supplementedwith fetal bovine serum
SFB) 10%. Besides displaying Pgp/ABCB1, Lucena cell line is resistant to oxidative
tress, ultraviolet-A radiation and has high catalase content [15]. Proteomic analysis
howed that Lucena presents 36 proteins differentially expressed, 14 dowregulated
nd 22 upregulated, in comparison to K562 cell line [16].
.2. Drugs
Imatinib mesylate (imatinib) and cyclosporine A (CSA, Atopica®) were
rovided by Novartis Brazil and diluted in RPMI-1640 prior to use. 1--d-
rabinofuranosylcytosine (cytarabine, ara-C) was provided by Meizler Biopharma,
razil. Stock solutions were stored at 4 ◦C.
.3. Analysis of cell viability
Thegrowth inhibitionof theCMLK562andLucena cell lineswasdeterminedbya
olorimetricMTT assay (MTT, GEHealthcare, USA) [17]. Brieﬂy, cellswere incubated
or 24, 48 and 72h in the presence or absence (control) of various concentrations
f imatinib (0.5, 1.0, 2.5, and 5.0M), ara-C (0.1, 0.5, 1.0, 2.5, 5.0, and 10.0M), and
he drugs in association. The plates were processed as described previously [18]. All
f the assays were performed in triplicate.
.4. Analysis of apoptosis rate
The CML cell lines were cultured for 24h in the presence of 0.5M imati-
ib, 10M ara-C, or the drugs in association. The percentage of apoptotic cells
as assessed using the Annexin V assay (Genzyme Diagnostics, USA) as described
reviously [18]. Propidium iodide (PI) was used to avoid necrotic cell detec-
ion (Annexin−/PI+). The drugs-induced apoptotic rate (Annexin+/PI− and Annexin
+/PI+) was comparedwith the apoptosis in the absence of the drugs used as control
spontaneous apoptosis).
.5. Determination of efﬂux pump activity modulation
TheCMLLucena cell linewas pre-incubatedwithCSA5g/mL (4.2M)ormain-
ained without CSA for 24h as described previously [19]. After that, cells with
SA were re-incubated with CSA alone or in association with 0.5M imatinib,
hile the cells without CSA were divided in two more groups, 0.5M imati-
ib and without any drug (control). All cells were maintained for an additional
4h and processed to analyze apoptosis rate by ﬂow cytometry as described
bove.
.6. Immunocytochemistry assay
TheCMLK562andLucena cell lineswere incubatedwith0.5Mimatinib, 10M
ra-C, the drugs in association, and without drugs (control) for 24h. The slides were
repared by centrifugation of the cultured cells in a cytospin centrifuge. The slides
ere ﬁxed and permeabilized with acetone and methanol for 10min. Then, cells
ere incubated with 2% H2O2 to block the endogenous peroxidase. Non-speciﬁc
taining was blocked using blocking solution [2% nonfat dry milk, 2,5% BSA (bovine
erum albumin), and 8% FBS q.s.p. 100mL tris-buffered saline (TBS)] for 1h, and pri-
ary polyclonal antibody against survivin (1:900 dilution, Sigma–Aldrich® , USA).
he cell slides were incubated at 4 ◦C overnight in a moist chamber. After washing
tep, secondary antibodies provided by DAKO LSAB2® System-HRP Kit were applied
s manufactures instructions. The cells were exposed to 2,4-diaminobenzidine
DAKO Liquid DAB+Substrate Chromogen System Kit), counterstained with Har-
is hematoxylin, dehydrated, and mounted. Omission of the primary antibody was
sed as a negative control. The immunostaining was analyzed with a Nikon Eclipse
200 microscope. A 100-fold increase in immersion was used for the visualization
20].
.7. Subcellular fractionationThe leukemic cell lines were incubated as described above. The cultured cells
ere washed twice with cold PBS (pH 7.4) and centrifuged at 200× g for 5min
t 4 ◦C. The pellet was resuspended in cold PBS and centrifuged at 800x g for 5min.
he supernatantwas removed, and the recipientwith dry pelletwas placed in nitro-
en vapor for 1min to promote cell lysis. The pellet was resuspended in 150L ofarch 36 (2012) 1510–1516 1511
hypotonic buffer A (1.5mMMgCl2, 10mMKCl, and 10mMTris–HCl; pH 7.9) supple-
mentedwith protease inhibitors, 1L aprotinin (1mg/mL) andpepstatin (1mg/mL),
0.4mMPMSF, and3mMDTT. Then0.05%TritonX-100was added. The sampleswere
centrifuged at 2500× g for 15min. The supernatant was collected as cytoplasmatic-
enriched fraction, and the pellet was resuspended in 150L of hypotonic buffer B
(20% glycerol, 1.5mMMgCl2, 10mMKCl, and 20mMTris–HCl; pH 7.9) and 100L of
hypertonic buffer C (20% glycerol, 1.5mMMgCl2, 1.2MKCl, and 20mMTris–HCl; pH
7.9). Both buffers were supplemented with protease inhibitors, 0.4mM PMSF, and
3mMDTT. The samplesweremaintained under agitation for 45min at 4 ◦C and cen-
trifuged at 16,000× g for 90min. The supernatantwas collected as nuclear-enriched
fractionand thepellet removed.All theprocedureswere realizedat4 ◦C, andsamples
were maintained in an ice bath. The nuclear and cytoplasmatic-enriched fractions
were stocked at −20 ◦C (adapted from Connell et al. [21]).
2.8. Western blotting analysis
After subcellular fractionation, the survivin expression was evaluated in the
cytoplasmatic and the nuclear fractions. The protein concentration was determined
by the Lowry method [22]. 60g of protein was subjected to SDS-PAGE on 15%
polyacrylamide gels, transferred to Hybond-P membranes (GE Healthcare) and
immunostained as described previously [14]. Primary antibodies were against sur-
vivin (1:1000 dilution; R&D Systems, USA), lamin B (1:500; Calbiochem, Germany)
orHSC70 (1:5000 dilution; Santa Cruz, USA). Secondary antibodieswere anti-mouse
(1:1000 dilution; Amershan Biosciences, USA), anti-rabbit (1:1000 dilution; Amer-
shan Biosciences, USA) or anti-goat (1:1000 dilution; Novus Biologicals, USA). The
expression of survivin was normalized with respect to HSC70 for the cytoplasmatic
fraction and lamin B for the nuclear fraction.
2.9. Statistical analysis
Statistical and graphical informationwas determined using the GraphPad Prism
software (GraphPad Software Incorporated). ANOVA variance test was used and p
values were reported at 95% conﬁdence intervals. The Bonferroni post test was used
to compare samples after treatments. A p value of <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Effect of imatinib and ara-C on the cell viability of the
sensitive and the resistant CML cell lines
The sensitive K562 and the resistant Lucena CML cell lines were
incubated with various concentrations of imatinib, ara-C and the
drugs in association. Imatinib reduced the cell viability in a time-
dependent but not dose-dependent manner in the K562 cells. The
lowest concentration (0.5M) suppressed cell viability by approx-
imately 25% (p>0.05), 62% (p<0.05), and 75% (p<0.01) after 24,
48, and 72h of incubation, respectively (Fig. 1A). The degree of cell
viability suppression was maintained at 1.0, 2.5, and 5.0M con-
centrations, showing statistically signiﬁcant results after 48 and
72h of incubation (p<0.01). Ara-C also caused a time-dependent
but not dose-dependent reduction in cell viability. Along the time,
all the concentrations tested showed the same picture of the cell
viability suppression. Within 24h of incubation, no alteration in
the cell viability was observed. After 48h, we observed an approxi-
mately 20% (p>0.05) decrease in the cell viability, which increased
to 40% (p<0.05) after 72h. Nevertheless, the concentration of
0.1M was not signiﬁcant at any of the times tested (p>0.05)
(Fig. 1B). The effect of imatinib combined with ara-C was similar to
the viability reduction achieved with the respective concentration
of imatinib alone (Fig. 1C). Imatinib 0.5M associated with differ-
ent ara-C concentrations showed a statistically signiﬁcant decrease
in cell viability after 48h (p<0.01) and 72h (p<0.001), as well the
associations with imatinib 1.0M (p<0.001). This result demon-
strated that in the sensitive cell line, there was no pharmacological
interaction between imatinib and ara-C when these drugs were
tested in combination.
The viability of the resistant Lucena cell line was suppressed by
0.5M and 1.0M imatinib concentrations similarly, by approx-
imately 15% (p>0.05), 41% (p>0.05), 70% (p<0.05) after 24,
48 and 72h of incubation, respectively (Fig. 1D). Greater con-
centrations of imatinib (2.5M and 5.0M) elicited a higher
1512 P.S. Bernardo et al. / Leukemia Research 36 (2012) 1510–1516
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pump activity is only partially responsible for the resistance phe-
nomemon in Lucena cell line.ig. 1. Viability of CML K562 and Lucena cell lines induced by imatinib and ara-C
*p<0.05, **p<0.01, ***p<0.001).
eduction in the cell viability, with a maximum reduction of 80%
ithin 72h of incubation (p<0.01). Ara-C caused a decrease of
pproximately 40% in the cell viability only after 72h incuba-
ion (p<0.05), similar to the observation in K562 cells (Fig. 1E).
n Lucena cells, imatinib associated to ara-C induced an effect
imilar to imatinib alone (Fig. 1F). Imatinib (0.5M) associated
ith ara-C 0.5M (p<0.05), 5M (p<0.05) and 10M (p<0.01)
howed a statistically signiﬁcant decrease in cell viability only
fter 72h, as well the associations with 1.0M of imatinib
p<0.01).
.2. Apoptosis induction by imatinib and/or ara-C in the CML cell
ines
As shown in Fig. 2A, imatinib was able to induce apoptosis in
pproximately 60% of the sensitive K562 cells. On the other hand,
his cell line was less sensitive to ara-C, which induced apoptosis in
2% of the cells. In the resistant Lucena cell line, the apoptosis index
nduced by imatinib was found to be of a lesser proportion (12%)
han the apoptosis rate observed in the sensitive cell line (60%), and
he differencewas statistically signiﬁcant (p<0.001). A similar apo-
tosis index was observed with ara-C treatment, which induced 8%
poptosis. When the drugs were tested in combination, the apo-
tosis index in the Lucena cells (approximately 30%) was higher
han the effects of either imatinib (12%) or ara-C (8%) separately,
ut this enhancement of apoptosis was not statistically signiﬁcant.
n the K562 cell line, no advantage was observed when drugs were
ssociated.
To evaluate if the imatinib resistance proﬁle exhibited by the
ucena cells was provided by the efﬂux pump activity of Pgp, its
fﬂux activity was modulated and the apoptosis rate measured
fter imatinib incubation. The modulation promoted an increase of
pproximately 8% in the apoptosis rate in comparison with imati-
ib alone (p<0.05) (Fig. 2B). As observed, the modulation was not
ble to induce the same apoptosis rate of the sensitive K562 cells,rmined by MTT assay after 24, 48 and 72h. Error bars represent± standard error
which was around 60%. This result demonstrates that the efﬂuxFig. 2. Apoptosis of CML K562 and Lucena cell lines induced by imatinib and ara-C
determined by the Annexin V assay. Leukemic cells incubated without the drugs
were used as control of spontaneous apoptosis (*p<0.05, **p<0.001).
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.3. Effect of imatinib and ara-C in the modulation of the
ubcellular localization of survivin in the sensitive K562 and the
esistant Lucena CML cell lines
Next, we fractionated the cells to investigate survivin subcell-
lar localization after treatment by Western blotting. As shown in
ig. 3, thebasal level of the survivin expressionwas similar between
he cytoplasmatic and nuclear pools in the sensitive (A) as well as
n the resistant (B) cell lines. After imatinib exposure, there was
predominant nuclear localization of survivin in the K562 cell
ine promoted by an increased expression in this compartment
nd with a consequent reduced expression in the cytoplasmatic
ne. This result is in agreement with the high percentage of apop-
otic cells induced by imatinib. On the other hand, there was a
redominant cytoplasmatic localization of survivin in the Lucena
ell line promoted by a reduced expression in the nuclear com-
artment (p<0.05). This result is also in agreement with the low
poptosis index induced by imatinib in this cell line. Conversely,
ra-C decreased survivin expression in both cell lines, and simi-
ar amounts of protein were seen between the compartments. The
ombination of imatinibwith ara-C, in the K562 cell line, promoted
slight reduction of the cytoplasmatic pool,while in the Lucena cell
ine, therewas a predominant cytoplasmatic localization promoted
y a reduction in the nuclear pool.
.4. Survivin subcellular modulation in the sensitive K562 and
he resistant Lucena CML after imatinib and/or ara-C
To further address the issue of whether imatinib or ara-C could
hift the survivin subcellular localization, we used an immunocy-
ochemistry assay. The K562 (Fig. 4B) and Lucena (Fig. 5B) cells
ncubated without the drugs (positive control) showed cytoplas-
atic and nuclear staining in accordancewith theWestern blotting
ata. Incubation of K562 cells with imatinib exhibited a predomi-
ant survivin nuclear staining as protein clusters, while in Lucena
ells, the staining was predominantly cytoplasmatic, with smaller
rotein clusters in the nucleus of the cells (Figs. 4C and 5C). Both
ell lines incubated with imatinib showed a less intense survivin
mmunostaining when compared with their controls, mainly in
he sensitive cell line. When incubated with ara-C, the sensitive
ell line exhibited a survivin pattern staining similar to that of the
ig. 3. Survivin levels in K562 and Lucena cells after subcelullar fractionation when expo
urity of the fractions. Data are from one of the three experiments with reproducible resuarch 36 (2012) 1510–1516 1513
cells incubated with imatinib, although in a more intense fashion
(Fig. 4D). The resistant cell line exhibited a predominant survivin
cytoplasmatic staining, which is in disagreement with the Western
blotting results (Fig. 5D). Finally, when the drugs were combined,
both cell lines showed reduced survivin levels in thenucleus in rela-
tion to their positive controls, corroborating the Western blotting
data (Figs. 4E and 5E).
The drugs promoted morphologic alterations. The ara-C treat-
ment resulted in bigger cells with a large nucleus (Figs. 4D and 5D).
After imatinib and the combined treatments, the sensitive cell line
showed a typical morphology of damaged cells, suggesting apop-
totic bodies (Fig. 4C and E). This morphologic feature was not seen
in the resistant cell line (Fig. 5C and E).
4. Discussion
Imatinib as a single drug has been shown to be ineffective, as
it produces a transient response in blast phase CML [23]. Thus, in
the present study we selected ara-C for the evaluation of a possi-
ble enhancement in cytotoxicity when combined with imatinib in
the treatment of two blast-phase CML cell lines. Besides, ara-C was
chosen due to the fact that its export from cells through Pgp, as a
drug substrate for this transporter protein, has not been completely
established [24,25]. The combined use of imatinib and ara-C did not
cause a decrease in the cell viability of both vincristine-sensitive
and -resistant cell lines. However, when we evaluated the induc-
tion of apoptosis by treatmentswith imatinib and/or ara-C through
the Annexin V/PI assay we observed signiﬁcantly different apopto-
sis indexes between the two cell lines. Imatinib was able to induce
a markedly higher apoptosis index in the CML K562 cell line, which
was more sensitive than CML Lucena cell line. This ﬁnding suggests
a cross-resistance between vincristine and imatinib, which can be
explained by the fact that Lucena cells overexpress Pgp. Moreover,
previous studies have shown that imatinib is a substrate for this
drug transporter protein [4,7,26]. Ara-C induced a low apoptosis
index in both cell lines, but when the drugs were combined, the
apoptosis index in the sensitive cells was similar to that found
with imatinib alone. However, the same combination of drugs in
the resistant cells elicited a slight increase in apoptotic cells when
compared to the cells exposed to single treatments. Although it
sed to imatinib and ara-C. HSC70 and lamin B controls ensure protein loading and
lts (*p<0.05).
1514 P.S. Bernardo et al. / Leukemia Research 36 (2012) 1510–1516
Fig. 4. Survivin subcellular localization in K562 cell line by imatinib (0.5M) and ara-C (10M) for 24h. (A) Negative control, (B) positive control in drug absence, (C)
imatinib, (D) Ara-C and (E) imatinib + ara-C. Arrows: suggestive apoptosis morphology after cellular chemotherapeutic exposition.
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matinib, (D) Ara-C and (E) imatinib + ara-C.
as not statistically signiﬁcant, this ﬁnding is in accordance with
revious works [27–29].
Here, we demonstrated that modulation of efﬂux pump activ-
ty by CSA was able to promote only a little increase of apoptosis
n Lucena cells. This ﬁnding suggests that the efﬂux pump activ-
ty is partially responsible for the drug resistance proﬁle in these
ells giving support to the theory of a relationship between Pgp
nd survivin as shown previously [12,14,19]. Some properties of
his biological phenomenon have become clear in the last years.
study conducted by Liu and collaborators [13] showed that sur-
ivin transcription was associated with Pgp/ABCB1 overexpression
hrough the PI3k/Akt pathway in breast cancer cell lines, suggest-
ng that survivin might play a key role in the MDR phenotype in
he presence of Pgp. Indeed, our group recently demonstrated that
urvivin and Pgp are associated and highly expressed in late but
ot in early chronic phase of CML, suggesting that this association
ay play a biological role in the disease progression [14]. Addition-
lly, we observed that the sensitive K562 (Pgp-negative) as well
s the resistant Lucena (Pgp-positive) cell lines displayed nuclear
nd cytoplasmatic survivin expression. Imatinib was capable of-C (10M) for 24h. (A) Negative control, (B) positive control in drug absence, (C)
modulating the survivin subcellular localization given that, after
treatment with this drug, the sensitive cell line exhibited survivin
predominantly in the nucleus compared to predominantly in the
cytoplasm in the resistant cell line. Furthermore, the induction of a
highpercentageof apoptosis in the sensitive cell linewasassociated
with the survivinmodulation to the nucleus and the reduction of its
cytoplasmatic expression. This is in agreement with the data in the
literature, which suggest that nuclear survivin is a better progno-
stic factor in some neoplasms, such as colorectal [30], breast [31],
lung [32], and pancreatic [33]. On the other hand, in the Lucena cell
line, the survivin cytoplasmatic localization was associated with
imatinib resistance, as conﬁrmed by the low apoptosis rate. This
ﬁnding is also in accordance with some studies in the literature
that showed cytoplasmatic survivin as an unfavorable prognostic
factor in pancreatic cancer [33], glioblastoma multiforme [34], and
colorectal carcinoma [35].Moreover, alternative splicing of the survivin gene can give rise
to ﬁve different mRNA isoforms (survivin-standard or wild type,
survivin-Ex3, survivin-2a, survivin-2B and survivin-3B), which
can present differential subcellular localization and, therefore,
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lso different functionality [36]. Speletas and collaborators [37]
emonstrated that patients at accelerated and blast phases of
ML displayed an increased expression of the survivin standard
ariant and signiﬁcant lower levels of the anti-apoptotic survivin-
Ex3, mainly found in nucleus, and the pro-apoptotic survivin
B, frequently found in cytoplasm, compared to normal cells, and
ompared to CML in chronic phase. In agreement with this, a
ossible limitation of our study could be the fact that the com-
ercial polyclonal antibody used in our immunocytochemistry
ssay cannot distinguish survivin isoforms. Instead, this antibody
as been shown adequate in assessing total survivin expression
38,39]. However, it is interesting to note that, through Western
lot analysis there was signiﬁcant positive correlation with the
RNA positivity of survivin standard, survivin-Ex3, survivin-2B
nd survivin-2a. All variants were correlated with poor prognosis.
his result demonstrates that not only speciﬁc anti-apoptotic iso-
orm, is associated with poor prognosis [40]. Another study used
uantitative RT-PCR to quantify the amount of mRNA of all ﬁve
urvivin variants [41]. It was observed that no association with
rognosis was found for the survivin-Ex3 or survivin-2B vari-
nts. However, despite the undoubted presence of survivin splice
ariants in diverse type of neoplasms their expression in tumor
ells is quite low. Therefore, it becomes necessary new method-
logies and more studies using speciﬁc monoclonal antibodies to
iscriminate survivin isoforms in different cancer cells [42]. More-
ver, most studies analyze mRNA might suffer post-translational
hanges, herein does not reﬂect survivin protein levels.
Despite the limited number of cell lines analyzed in the present
tudy, it is important toemphasize that these cell lines areundoubt-
dly different. In addition to Pgp expression, Lucena cells present
igh expression of the Oct-4, ABCG2, ABCB1, BCR-ABL and OCT1
enes as compared to K562 cells [16,43].
In conclusion, we showed that imatinib was able to modulate
he subcellular localization of survivin and increase the apopto-
is rate in the sensitive K562 cell line. In the resistant Lucena cell
ine, the cytoplasmatic localization of survivin was associated with
ts antiapoptotic activity, this being in agreement with the smaller
poptosis index observed in these cells. Since there was a differ-
nt mobilization of survivin in the cell compartments triggered by
matinib in Pgp-negative and Pgp-positive cells, our results sug-
est a relationship between survivin and Pgp. However, as our
tudy is the ﬁrst to evaluate the subcellular localization of sur-
ivin after treatment with imatinib and ara-C in CML cells, it is
ot possible to compare our ﬁndings with those of other studies.
urther exploration to conﬁrm these ﬁndings is warranted. There-
ore,we speculatewhether Pgp and survivin are subject to the same
olecular regulation. Consequently, targeting this common path-
ay might be an innovative approach in the treatment of blast
hase CML.
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